AN2 Therapeutics, Inc. 8-K

What Happened
AN2 Therapeutics, Inc. (ANTX) held its 2026 annual meeting of stockholders on June 3, 2026 and filed an 8-K on June 9, 2026 reporting the certified voting results. Holders of 22,741,535 shares (63.18% of 35,995,545 shares outstanding as of the April 15, 2026 record date) were present in person or by proxy, constituting a quorum. Stockholders voted to elect three Class I director nominees and to ratify PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Quorum: 22,741,535 shares present, representing 63.18% of 35,995,545 shares outstanding (record date April 15, 2026).
• Director elections (each elected for term through 2029 unless successor elected):
  • Kabeer Aziz: 13,547,536 votes FOR; 3,958,874 WITHHELD; 5,235,125 broker non-votes.
  • Gilbert Lynn Marks, M.D.: 15,947,854 FOR; 1,558,556 WITHHELD; 5,235,125 broker non-votes.
  • Rob Readnour, Ph.D.: 15,920,563 FOR; 1,585,847 WITHHELD; 5,235,125 broker non-votes.
• Auditor ratification: PricewaterhouseCoopers LLP ratified with 22,724,674 FOR, 13 AGAINST, and 16,848 ABSTENTIONS.

Why It Matters
The meeting confirmed the company’s governance slate and reappointed its external auditor—routine but important corporate housekeeping for investors. The certified vote totals show a quorum was achieved and provide transparency on shareholder support levels (including withheld votes and broker non-votes), which investors can use to assess board endorsement and governance stability.